1. Home
  2. MLYS vs RGR Comparison

MLYS vs RGR Comparison

Compare MLYS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.93

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Sturm Ruger & Company Inc.

RGR

Sturm Ruger & Company Inc.

HOLD

Current Price

$40.50

Market Cap

601.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
RGR
Founded
2019
1949
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ordnance And Accessories
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
601.9M
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
MLYS
RGR
Price
$27.93
$40.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$48.67
$43.00
AVG Volume (30 Days)
1.1M
117.4K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
1.07%
EPS Growth
37.43
N/A
EPS
N/A
0.44
Revenue
N/A
$546,057,000.00
Revenue This Year
N/A
$2.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$91.23
Revenue Growth
N/A
1.94
52 Week Low
$22.30
$28.33
52 Week High
$47.65
$48.21

Technical Indicators

Market Signals
Indicator
MLYS
RGR
Relative Strength Index (RSI) 50.33 66.07
Support Level $25.56 $36.76
Resistance Level $28.14 $40.93
Average True Range (ATR) 1.68 0.91
MACD -0.06 0.25
Stochastic Oscillator 39.69 97.57

Price Performance

Historical Comparison
MLYS
RGR

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: